araag2/HINT huggingface dataset:
Clinical trial NCT03206749 (phase 2, status: completed)
Conditions: acute pain
ICD codes: G89.12, G89.18, G89.11, G89.3
Drugs: vx-150, hb/apap, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Prior to Surgery:

          -  Body mass index (BMI) of 18.0 to 38.0 kg/m2, inclusive

          -  Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair,
             without collateral procedures, under regional anesthesia (Mayo and popliteal sciatic
             block) not to include base wedge procedure

        After Surgery:

          -  Subject reported pain of ≥4 on the NPRS, and moderate or severe pain on the Verbal
             Categorical Rating Scale (VRS) within 9 hours after removal of the popliteal sciatic
             block on Day 1

          -  Subject is lucid and able to follow commands

          -  All analgesic guidelines were followed during and after the bunionectomy

        Exclusion Criteria:

        Prior to Surgery:

          -  History in the past 10 years of malignancy, except for squamous cell skin cancer,
             basal cell skin cancer, and Stage 0 cervical carcinoma in situ

          -  History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)

          -  History of abnormal laboratory results ≥2.5 × upper limit of normal (ULN)

          -  History of peripheral neuropathy

          -  A known or clinically suspected infection with human immunodeficiency virus or
             hepatitis B or C viruses

          -  Prior medical history of bunionectomy or other foot surgery

          -  Intolerant of or unwilling to receive hydrocodone, acetaminophen, or ibuprofen

          -  For female subjects: Pregnant, nursing, or planning to become pregnant during the
             study or within 90 days after the last study drug dose

          -  For male subjects: Male subjects with a female partner who is pregnant, nursing, or
             planning to become pregnant during the study or within 90 days after the last study
             drug dose

        After Surgery:

          -  Subject had a type 3 deformity requiring a base wedge osteotomy or concomitant surgery
             such as hammertoe repair; or experienced medical complications during the bunionectomy
             that, in the opinion of the investigator, should preclude randomization

        Other protocol defined inclusion/exclusion criteria may apply.
Clinical trial NCT03222323 (phase 2, status: unknown status)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: dexmedetomidine perineurally, ropivacaine 5mg/ml, ropivacaine 7.5mg/ml, dexmedetomidine systemically, isotonic saline
SMILES: C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1, CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C, CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C, C[C@H](C1=CNC=N1)C1=C(C)C(C)=CC=C1, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must understand the protocol fully and sign the written in-formed
             consent.

          -  ASA 1-2

          -  BMI > 18 to < 30

          -  For fertile women: safe contraceptives for the last month and a nega-tive urin HCG.

        Exclusion Criteria:

          -  Participants unable to cooperate in the trial.

          -  Participants unable to speak or read Danish

          -  Allergy to study medication.

          -  Alcohol consumption >21 units for men and >14 for women per week

          -  Daily intake of prescription painkillers within the last 4 weeks.

          -  Over the counter painkillers during the last 48 hours.

          -  Neuromuscular defects or wounds on the arms or hands preventing test performance.

          -  Diabetes Mellitus

          -  2. degree heart block

          -  Sick sinus node.

          -  For fertile women a positive urine HCG
Clinical trial NCT03224351 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: tez/iva, vx-659, iva, matched placebos, tez, vx-561
SMILES: CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, CC(C)(CO)C1=CC2=CC(NC(=O)C3(CC3)C3=CC=C4OC(F)(F)OC4=C3)=C(F)C=C2N1C[C@@H](O)CO
Eligibility criteria:

        Key Inclusion Criteria:

          -  Body weight ≥35 kg.

          -  Subjects must have an eligibleCFTR genotype.

               -  Part 1 and Part 3: Heterozygous for F508del and an MF mutation (F/MF)

               -  Part 2: Homozygous for F508del (F/F)

          -  FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height

        Key Exclusion Criteria:

          -  History of clinically significant cirrhosis with or without portal hypertension.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency

          -  Lung infection with organisms associated with a more rapid decline in pulmonary
             status.

          -  History of solid organ or hematological transplantation.

        Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT03228394 (phase 2, status: completed)
Conditions: depression, depressive disorder, depression, postpartum, behavioral symptoms, mood disorders, mental disorders, puerperal disorders, pregnancy complications, postpartum, ppd
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32, F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F53.0, F34.81, F39, F34.9, F43.21, F10.14, F10.24, F11.14, F48.9, F99, F51.05, F51.13, F09, F06.8, F48.8, O04.80, O04.89, O22.8X1, O22.8X2, O22.8X3, O22.8X9, O04.85
Drugs: ganaxolone, placebo
SMILES: [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@](C)(O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject experienced a Major Depressive Episode, which started between the start of the
             third trimester and 4 weeks following delivery. The Major Depressive Episode must be
             diagnosed according to MINI 7.0 interview

          -  Subject gave birth in the last 6 months

          -  Subject has a HAMD17 score of ≥ 26 at screening

          -  Subject must agree to stop breastfeeding from start of study treatment or must agree
             to temporarily cease giving breast milk to her infant(s)

        Exclusion Criteria:

          -  Current or past history of any psychotic illness, including Major Depressive Episode
             with psychotic features

          -  History of suicide attempt within the past 3 years

          -  Active suicidal ideation

          -  History of bipolar I disorder

          -  History of seizure disorder
Clinical trial NCT03233308 (phase 2, status: completed)
Conditions: primary open angle glaucoma or ocular hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: netarsudil ophthalmic solution 0.02%
SMILES: CC1=CC(C)=C(C=C1)C(=O)OCC1=CC=C(C=C1)[C@@H](CN)C(=O)NC1=CC=C2C=NC=CC2=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Must be 18 years of age or older

          2. Diagnosis of open primary angle glaucoma(POAG) or ocular hypertension (OHT) in both
             eyes

          3. Unmedicated intraocular pressure (IOP) >20 mmHg and < 30 mmHg in both eyes at first
             qualification visit

          4. Best corrected visual acuity (BCVA) equivalent to 20/200 Snellen or better

          5. Able to give informed consent and follow study instructions

        Exclusion Criteria:

        Ophthalmic:

          1. Clinically significant ocular disease

          2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure
             glaucoma, or narrow angles

          3. Intraocular pressure ≥30 mmHg in either eye

          4. A difference in IOP between eyes >4mmHg at qualification visit

          5. Use of more than two ocular hypotensive medications within 30 days of screening

          6. Known hypersensitivity to any component of the formulation

          7. Previous glaucoma surgery or refractive surgery

          8. Keratorefractive surgery in either eye

          9. Report of ocular injury in either eye within the six months prior to screening or
             ocular or non-refractive surgery within 3 months prior to screening

         10. Recent or current ocular infection or inflammation in either eye

         11. Use of ocular medication in either eye of any kind within 30 days of screening

         12. Mean central corneal thickness greater than 620 μm in either eye

         13. Any abnormality preventing reliable applanation tonometry of either eye

         14. Lack of suitable episcleral vein prior to performing Episcleral Venus Pressure (EVP)
             measurement (applicable to 1 site only)

             Systemic:

         15. Clinically significant abnormalities within 6 weeks prior to screening

         16. Clinically significant systemic disease

         17. Participation in any investigational study within 60 days prior to screening

         18. Use of systemic medication that could have an effect on intraocular pressure within 30
             days prior to screening

         19. Women of childbearing potential who were pregnant, nursing, planning a pregnancy, or
             not using a medically acceptable form of birth control
Clinical trial NCT03233529 (phase 2, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: crisaborole ointment 2% bid, placebo ointment (vehicle)
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of active atopic dermatitis (AD) with at least 6 month history
             prior to Screening and that has been clinically stable for 1 month.

          -  Investigator's Static Global Assessment (ISGA) of 2 (mild) or 3 (moderate) at
             Baseline.

          -  Body surface area (BSA) covered with AD of at least 0.5% and no more than 10% at
             Baseline, calculation excluding face, scalp, axilla, genitals, groin area, palms, back
             of the hands, and soles.

          -  Two lesions of AD at least 3 cm x 3 cm in size and at least 5 cm apart, with identical
             Lesion ISGA score of greater than/equal to 3.

        Exclusion Criteria:

          -  Clinically infected AD or requires high potency topical corticosteroids or systemic
             (oral/injectable) corticosteroids to manage AD.

          -  History of angioedema or anaphylaxis to topical products or known sensitivity to
             components of crisaborole ointment 2%.

          -  History of cancer (except squamous or basal cell carcinoma or carcinoma in situ of the
             skin).

          -  Previous treatment with any topical or systemic PDE4 inhibitor unless stopped for the
             reason of lack of efficacy.
Clinical trial NCT03234842 (phase 2, status: withdrawn)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    non-accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must be at least 18 years at the time of consent.

          -  Pathologically confirmed esophageal adenocarcinoma or squamous cell. carcinoma of the
             thoracic esophagus or esophagogastric junction.

          -  Patient's preliminary cancer stage, according to the AJCC 7th edition staging, must be
             cT1b-T4, N0-N3.

        Exclusion Criteria:

          -  Patients with cervical esophageal carcinoma.

          -  Prior radiotherapy with fields overlapping the current esophageal cancer.

          -  Patients with cT1a disease.

          -  Patients with evidence of tracheoesophageal fistula must undergo bronchoscopy to
             exclude fistula.

          -  Patients with distant metastatic disease.
Clinical trial NCT03241342 (phase 2, status: completed)
Conditions: stress urinary incontinence
ICD codes: N39.41, N39.46, N39.490, N39.491, N39.492, R32, R39.81
Drugs: gtx 024, placebo
SMILES: C[C@](O)(COC1=CC=C(C=C1)C#N)C(O)=NC1=CC(=C(C=C1)C#N)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  SUI symptoms of at least 6 months duration

          -  Predominant SUI as determined at the Screening Visit using the Medical,
             Epidemiological, and Social Aspects of Aging (MESA) urinary questionnaire.

          -  24-Hour pad weight > 3 g during the screening period

          -  A minimum of 1 and no more than 15 SUI episodes on any single day AND no fewer than 9
             total SUI episodes over 3 days during the screening period

          -  Positive bladder stress test conducted during the Screening Visit

        Key Exclusion Criteria:

          -  History of pelvic radiation treatment

          -  History of urethral diverticula

          -  History of urethral sling or anterior prolapse repair

          -  Treatment with urethral bulking agents and/or other SUI procedure or surgery within
             the 6 months prior to the Screening Visit

          -  Known vesicoureteral reflux, vaginal prolapse beyond the introitus, or other
             significant pelvic floor abnormalities

          -  Urinary incontinence of neurogenic etiology

          -  Morbidly obese (defined as 100 pounds over ideal body weight, or body mass index 40 or
             greater)

          -  Chronic hepatitis

          -  Hepatic cirrhosis

          -  Evidence of active infection with hepatitis B or hepatitis C

          -  History of human immunodeficiency virus (HIV) infection

          -  Subjects with a history of breast or endometrial cancer
Clinical trial NCT03246971 (phase 2, status: completed)
Conditions: acute pain, bunion, abdominoplasty
ICD codes: G89.12, G89.18, G89.11, G89.3, M21.611, M21.612, M21.619, M21.621, M21.622, M21.629
Drugs: wafermine™ 50 mg, wafermine™ 75 mg, placebos, wafermine™ 25 mg
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Scheduled for a bunionectomy or mini abdominoplasty with no additional planned
             procedures.

          -  Good general health without clinically significant renal, hepatic, cardiac or
             respiratory disease, as determined by the Investigator.

        Exclusion Criteria:

          -  For those undergoing bunionectomy, other painful conditions involving the surgical
             foot.

          -  Positive lab values for Hepatitis B or C or HIV
Clinical trial NCT03254186 (phase 2/phase 3, status: withdrawn)
Conditions: tardive dyskinesia
ICD codes: K22.4, G24.01
Drugs: propranolol hydrochloride, placebo oral tablet
SMILES: CC(=O)OC1=CC=C(C=C1)C(C1=CC=C(OC(C)=O)C=C1)C1=CC=CC=N1, CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    no participants
  
Eligibility criteria:

        Inclusion Criteria:

          -  age 18-75 years

          -  diagnosis of classical TD by a movement disorder expert for at least 6 months with a
             baseline score of at least 2 on two of the seven items on the AIMS severity scale

          -  stable on medication (either on or off dopamine blocking agents) for at least six
             months.

        Exclusion Criteria:

          -  breastfeeding

          -  pregnant

          -  unstable psychiatric disease

          -  history of asthma or COPD

          -  baseline heart rate less than 60

          -  history of orthostatic hypertension or its presence at screening

          -  history of congestive heart failure or unstable angina pectoris

          -  resting SBP <100 and DBP < 60

          -  AV-block II or III without pacemaker

          -  history of diabetes mellitus

          -  previous adverse effects from use of beta-blockers

          -  current use of a β-blocker and the other following drugs: quinidine, amiodarone,
             propafenone, digoxin, verapamil, diltiazem, clonidine, and warfarin

          -  tremor, dystonia, akathisia or other non-tardive movement disorder

          -  any medical illness that precludes treatment with propranolol.
Clinical trial NCT03254368 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus, overweight and obesity
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, E66.3
Drugs: zgn-1061, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Subjects must meet the following criteria to participate in this study:

          -  Be between the ages of 18 and 70 years, inclusive.

          -  Overweight or obese with a body mass index of at least 27 kg/m².

          -  Have type 2 diabetes with HbA1c between 7% and 11%.

          -  For subjects taking approved antidiabetes medications, the doses must be stable as
             determined by the study doctor.

          -  For subjects who have had weight-loss surgery (example: gastric banding), the
             procedure must have occurred at least 1 year ago, and be verified with documentation
             or by a health professional associated with the surgery.

        Exclusion Criteria:

        Subjects cannot participate in this research study if they meet any of the following:

          -  Have taken another study drug or study device within the past 6 months.

          -  Are taking certain prescribed medications including narcotics or opiates.

          -  Consistent recent use of insulin.

          -  Have had recent major surgery or prolonged bed rest, or planning or likely to undergo
             any surgery during the research study.

          -  Have a history of bleeding disorders or risk factors for excessive blood clotting.

          -  Have difficulty giving blood.

          -  Have a history of drug and/or alcohol abuse.
Clinical trial NCT03254511 (phase 2, status: unknown status)
Conditions: esophageal neoplasms
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: enoxaparin sodium 40 mg/0.2 ml subcutaneous injectable, chemotherapeutic combinations
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Definitive diagnoses of esophageal squamous cell carcinoma by pathological evaluation

          -  Non-metastatic esophageal cancer

          -  Patient who are candidate for chemo-radiation treatment

          -  Normal complete blood count

          -  Normal kidney function test

          -  Normal liver function test

          -  Normal fasting blood sugar

        Exclusion Criteria:

          -  Previous history of chest wall radiotherapy

          -  Previous history of chemotherapy

          -  Past medical history of Hypertension, diabetes mellitus, renal failure and liver
             failure

          -  Pathological report of adenocarcinoma or small cell carcinoma, neoplasm of other
             organs

          -  Discontent for the study

          -  Inability to do daily radiotherapy

          -  Unwillingness to esophagectomy
Clinical trial NCT03256526 (phase 2, status: completed)
Conditions: non-alcoholic fatty liver disease
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: placebo, pf-06835919 low dose, pf-06835919 high dose
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  BMI at least 28 kg/m2

          -  Type 2 diabetes and/or metabolic syndrome

        Exclusion Criteria:

          -  Liver disease

          -  Type 1 diabetes

          -  Recent heart attack or stroke

          -  Inability to have an MRI scan
Clinical trial NCT03256552 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: glycopyrronium mdi 28.8 micrograms, glycopyrronium mdi 14.4 micrograms, glycopyrronium mdi 7.2 micrograms, placebo mdi
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical history of COPD with a moderate to severe classification

          -  Current and former smokers with a history of at least 10 pack-years of cigarette
             smoking.

        -Post-bronchodilator FEV1 must be ≥30% and <80% predicted normal value-

        Exclusion Criteria:

          -  Pregnancy

          -  Primary asthma diagnosis; Poorly controlled COPD defined as acute worsening of COPD
             that required treatment with corticosteroids or antibiotics in the 6-week interval
             prior to Screening or between Screening and Visit 2;

          -  Clinically significant abnormal ECG

          -  Other active pulmonary disease such as active tuberculosis, lung cancer,
             bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension,
             interstitial lung disease, and uncontrolled sleep apnea; Cancer that was not in
             complete remission for at least 5 years;

          -  Diagnosis of angle closure glaucoma

          -  A documented myocardial infarction within 1 year of Screening.
Clinical trial NCT03258502 (phase 2, status: completed)
Conditions: respiratory syncytial virus infections
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: rv521, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 to 45 years, inclusive

          -  In good health with no history of major medical conditions

          -  A total body weight ≥ 50 kg and a body mass index (BMI) of >/=18kg/m2 and </=30kg/m2

        Exclusion Criteria:

          -  Evidence of any clinically significant or currently active major medical condition

          -  Positive for Human Immunodeficiency Virus, active Hepatitis A, B or C test

          -  Significant nose or nasopharynx abnormalities

          -  Abnormal lung function

          -  History or currently active symptoms suggestive of upper or lower respiratory tract
             infection